Bridgeway Capital Management’s Pacira BioSciences PCRX Stock Holding History

Bridgeway Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Hold	411,373	–	–	0.18%	171
2026 Q1	$9.3M	Sell	411,373 -29,832	-7%	-$663K	0.19%	162
2025 Q4	$11.4M	Sell	441,205 -3,533	-0.8%	-$84K	0.24%	121
2025 Q3	$11.5M	Sell	444,738 -15,535	-3%	-$382K	0.24%	125
2025 Q2	$11M	Buy	460,273 +31,744	+7%	+$800K	0.26%	110
2025 Q1	$10.6M	Buy	428,529 +69,744	+19%	+$1.67M	0.27%	108
2024 Q4	$6.76M	Buy	358,785 +11,149	+3%	+$196K	0.15%	201
2024 Q3	$5.23M	Buy	+347,636	New	+$5.94M	0.11%	266
2021 Q4	–	Sell	-8,300	Closed	-$465K	–	1316
2021 Q3	$465K	Buy	+8,300	New	+$478K	0.01%	1056

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's PCRX Position: Q2 2026 in Review

Bridgeway Capital Management held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 411,373 shares worth $10.4M. The position accounts for 0.18% of the portfolio, ranked #171.

Bridgeway Capital Management first reported a position in PCRX in Q3 2021 and has held it in 9 quarters since. The position peaked at $11.5M in Q3 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Bridgeway Capital Management held 411,373 shares of Pacira BioSciences worth $10.4M as of Q2 2026.
Bridgeway Capital Management left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up 0.18% of Bridgeway Capital Management's portfolio in Q2 2026, its #171 holding.
Bridgeway Capital Management first reported a position in Pacira BioSciences in Q3 2021 and has held it in 9 quarters since.
Bridgeway Capital Management's Pacira BioSciences position peaked at $11.5M in Q3 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.